ArticleFolia microbiologica2025
Pichia kudriavzevii yeast cell wall as a novel source of β-glucan: Extraction, characterization, and prebiotic functionality.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this study, β-glucan extraction was optimized from the Pichia kudriavzevii M10 strain, which was randomly selected from five yeast candidates (M5, M10, M13, M16, and M57). The goal was not only to maximize extraction yield but also to thoroughly characterize the structural and functional properties of the obtained β-glucan. β-glucan yields from cell walls were evaluated under optimized extraction conditions (inoculation, autolysis, hot water, sonication, and protease). Among the five yeast strains initially screened, P. kudriavzevii M13 exhibited the highest β-glucan content (87.8%) and was therefore selected for the optimization process and further analysis of its prebiotic properties. Fermentability of β-gluM13 by Ligilactobacillus plantarum GD2, Bifidobacterium bifidum A12, and Saccharomyces cerevisiae BD1 was assessed. Viability of these strains increased in media with β-gluM13 as the sole carbon source compared to controls. Lactobacillus Growth-Promoting (LGP), Bifido Growth-Promoting (BGP), and Yeast Growth-Promoting (MGP) activities of β-gluM13 at 0.5-10 mg/mL were compared with inulin. The highest LGP, BGP, and MGP activity were designated in the media containing 10 mg/mL (9.4 ± 0.1 log CFU/mL), 5 mg/mL (9.4 ± 0.1 log CFU/mL), and 10 mg/mL (9.4 ± 0.3 log CFU/mL) β- gluM13, respectively. Antioxidant activity of β-gluM13 (0.2-50 mg/mL) was measured via DPPH (2,2-diphenyl-1-picrylhydrazil) assay, showing lower activity than ascorbic acid. Gastrointestinal stability was tested in simulated gastric and bile fluids; β-gluM13 exhibited minimal hydrolysis (1.14% at 5 mg/mL, pH 2, 180 min; 1.16% at 10 mg/mL, 0.5% bile). β-gluM13's notable LGP, BGP, and MGP activities, moderate antioxidant properties, and gastrointestinal stability suggest its potential for gut health and functional food applications.
Indexed as
Identifiers
41196550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.